Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.
10.01.13: Cydan Expands Initial Financing to $26 Million; Lundbeckfond Ventures and Bay City Capital Join Diverse Investor Syndicate With Participation from NEA and Alexandria Venture Investments
07.09.13: Kurma Life Sciences Partners and Cydan Enter Collaboration to Further Expand Global Network and Strengthen Ability to Identify New Rare Disease Assets